Hungarian health bill changes may increase burden on drugmakers

In Hungary

Hungarian lawmakers last night approved an amendment to a healthcare bill that may force drugmakers to pay more to the state-monopoly medical insurer next year than planned in earlier legislation, Bloomberg reported.

Under the proposal, companies would be forced to return as much as 19% of the state subsidies they get for their medicines. The original version called for a rebate of either 14% or 16%. Egis Nyrt, Hungary's second biggest drugmaker, will probably end up paying more to the government because of the change, CFO László Marosffy said today. He said 54% of Egis's products are priced above Ft 2,000, the level when the 19% reimbursement would kick in.
Lawmakers will amend the bill again “to express more justice,” said Mihály Kökény, a former health minister who now heads Parliament's Health Committee. The bill is set for a final vote on Nov. 20. “The fees really should be paid by those actors, and on those drugs, that have a very quick increase in trade, as well as in social insurance payments,” Kökény said in a telephone interview today. “We do think that the cheaper drugs should get some kind of preference.”
Under the current amendment, companies will pay 11% on reimbursements for drugs with producer prices of Ft 1,000 or less, 17% on drugs that cost Ft 2,000 or less and 19% on drugs priced higher than Ft 2,000.
Egis and Richter Gedeon Nyrt, eastern Europe's biggest drugmaker, both issued profit warnings after Health Minister Lajos Molnár introduced his “drug thrift” bill last month. The law is designed to rein in state spending on medicines, which ballooned to Ft 348.9 billion last year from Ft 179.5 billion in 2001, according to data from Hungary's National Health Fund Administration (OEP).


Continental Dohányipari Revenue Nears HUF 64 bln in 2022 Figures

Continental Dohányipari Revenue Nears HUF 64 bln in 2022

Parl't Approves Amendments to Legislation on Judiciary Parliament

Parl't Approves Amendments to Legislation on Judiciary

CEE VC Funding Nosedives in Q1 - Vestbee Ecosystem

CEE VC Funding Nosedives in Q1 - Vestbee

Borsodi Friss Receives Revamped Look Drinks

Borsodi Friss Receives Revamped Look


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.